Credit Suisse Ag Aadi Bioscience, Inc. Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Shares
3 transactions
Others Institutions Holding AADI
# of Institutions
55Shares Held
12.6MCall Options Held
23.8KPut Options Held
0-
Avoro Capital Advisors LLC New York, NY2.85MShares$6.72 Million0.09% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2MShares$4.72 Million2.42% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$4.36 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.85MShares$4.35 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$1.81 Million0.0% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $49.6M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...